In an expansion of artificial intelligence into experimental healthcare, San Francisco startup Coherence has secured $45 million in a seed funding round backed by OpenAI. The investment highlights the rising curiosity of major AI organizations in neural information gathered directly from the human brain. Unlike traditional brain-computer interface developers that concentrate primarily on assisting paralyzed individuals through cursor manipulation or synthesized speech, Coherence is pursuing a unique medical application: deploying machine intelligence to detect and treat brain cancer directly inside the skull.
The Convergence of Neural Data and Artificial Intelligence
Brain-computer interfaces generate colossal amounts of raw neural activity that are far too dense for conventional human analysis. According to Coherence chief executive and cofounder Ben Woodington, there is a natural alignment forming between frontier AI laboratories and specialized device builders. Woodington points out that capturing neural signals to train sophisticated algorithms and subsequently tailoring patient treatments will become increasingly vital. Artificial intelligence provides the compute power needed to process these sprawling electrical streams and decipher underlying neurological events, offering a strong framework for complex medical applications.
Identifying Brain Tumors and Early Testing in Australia
Coherence is teaching its AI algorithms to decode tiny, faint electrical patterns generated by brain tumors. Prior work in animal subjects demonstrated that the platform can accurately determine whether a tumor is expanding, diminishing, or returning after remission. The development team is actively working to shift these early laboratory successes into broader human clinical testing.
Initial feasibility and safety assessments were conducted during the summer at the Royal Melbourne Hospital in Australia. Surgeons placed the recording implant into the brains of 3 patients who were already undergoing surgical procedures to remove brain tumors. The device recorded brain activity for approximately 30 minutes before removal, establishing a baseline safety check. Coherence is moving forward with an expanded trial involving 7 additional patients to evaluate both the recording fidelity and the electrical stimulation features of the hardware.
Halting Cancer Growth and Future Clinical Trials
The implant is built with a dual purpose: gathering live diagnostic data while administering subtle electrical stimulation to suppress tumor proliferation. The long-term vision is an adaptive device that continually learns cancer signatures and delivers real-time therapeutic pulses within the brain. Coherence will deploy the new $45 million capital injection to initiate clinical trials involving permanent, long-term implants for patients suffering from glioblastoma, a particularly lethal and fast-moving form of brain cancer. Over time, the company hopes to adapt this bioelectric strategy to treat cancerous tumors located in other areas of the body.
Ian Hathaway, a partner at the OpenAI Startup Fund, noted in a statement that Coherence is pioneering an innovative approach to oncology that steadily refines its therapeutic impact through incoming data, emphasizing pride in backing their efforts.
Data Separation and Big Tech's Neural Ambitions
The gathering of intimate neural recordings naturally brings data governance and patient confidentiality to the forefront. Woodington made clear that OpenAI will have no access to the patient records or neural information gathered by the implants. He confirmed that the investment agreement contains no provisions granting outside parties access to proprietary brain or medical data.
This distinct arrangement contrasts with OpenAI's earlier collaboration with Merge Labs, an ultrasound-based neural startup cofounded by OpenAI chief executive Sam Altman that emerged with $252 million in funding in January. In that deal, OpenAI committed to actively partnering on scientific foundation models to advance natural human-machine interfaces. The wider neurotech space has attracted significant venture attention, including Peter Thiel's venture capital firm backing Elon Musk's Neuralink as well as CTRL-labs, the wristband neural interface developer acquired by Facebook in 2019. Coherence now adds a dedicated oncological dimension to this rapidly growing frontier.
